SEC Filing Summary: Obalon Therapeutics, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Obalon Therapeutics, Inc. on May 30, 2019. The registrant is a Delaware corporation with its principal executive offices in Carlsbad, California. The company trades under the symbol OBLN on the NASDAQ Global Market and is classified as an emerging growth company.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding corporate governance and does not contain financial statements or performance metrics.
Material Changes
The primary material change disclosed is the rescheduling of the Company's 2019 Annual Meeting of Stockholders. The meeting date has been changed to Tuesday, July 23, 2019. This represents a shift of more than 30 days from the anniversary date of the 2018 Annual Meeting.
Guidance, Outlook, and Management Commentary
Management has established a new deadline for stockholder proposals intended for inclusion in the 2019 proxy statement. To be considered timely under Rule 14a-8, proposals must be received by 5:00 p.m. Eastern Time on June 9, 2019. Proposals must be directed to the Corporate Secretary at the principal executive offices. The exact time and location of the annual meeting will be detailed in the upcoming proxy statement.
Key Facts for Investor Verification
- Annual Meeting Date: Tuesday, July 23, 2019.
- Proposal Deadline: June 9, 2019, by 5:00 p.m. Eastern Time.
- Submission Address: 5421 Avenida Encinas, Suite F, Carlsbad, California, 92008 (Attention: Corporate Secretary).
- Reason for Filing: Compliance with Rule 14a-5(f) due to a date change exceeding 30 days from the prior year's anniversary.